Blockade of CD200 immune checkpoint has also been explored in a clinical trial phase 1 with samalizumab, a recombinant humanized monoclonal antibody that targets CD200, in relapsed or refractory B-cell chronic lymphocytic leukemia and multiple myeloma. This evidence concerns the gene CD200 and plasma cell myeloma.